This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential eligibility for bisphosphonate treatment.
Read moreSource BioScience, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-st...
Read moreThis pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates
Read moreThe MAF-TEST® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosp...
Read moreInbiomotion SL has announced that Alta Life Sciences has led its significantly oversubscribed investment round. Alta Life Sciences Spain I FCR is a leading venture capital fund managed by Altamar P...
Read moreThe fund is driven by ”la Caixa” and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme an...
Read moreIn the final round of selection, the European Horizon 2020 has chosen two Catalan start-ups from the health sector: Inbiomotion and Peptomyc, which will receive €50,000 to fund their innovative proj...
Read moreA study published in the Journal of National Cancer Institute (JNCI) by ICREA researcher Roger Gomis may be key to the early detection of patients at risk of developing metastasis to the bone. This ne...
Read more